GCM
CAPR icon

Gables Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Gables Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$2K – 368
2020
Q2 		$2K Buy
+500
New +$2.18K ﹤0.01% 339

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Gables Capital Management's CAPR Position: Q3 2020 in Review

Gables Capital Management sold out of Capricor Therapeutics (CAPR) in Q3 2020, closing a stake of 500 shares — an estimated $2K sold.

Gables Capital Management first reported a position in CAPR in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 25 funds tracked by Wall St. Rank hold CAPR as of Q3 2020.

  • Gables Capital Management reported no remaining Capricor Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Gables Capital Management sold 500 Capricor Therapeutics shares in Q3 2020, an estimated $2K.
  • Gables Capital Management first reported a position in Capricor Therapeutics in Q2 2020 and held it in 1 quarter.
  • Gables Capital Management's Capricor Therapeutics position peaked at $2K in Q2 2020.
  • 25 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2020.

Based on Gables Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.